Search

everythinglearnresearchcommunity

for

Search:↓

Autoimmune and metabolic issues are linked, and treating one may worsen another.

Early balding at 40 increases prostate cancer risk.

Medium-dose prednisolone pulse therapy is effective and safe for multifocal alopecia areata but not for more severe forms.

Old treatments for other skin conditions showed promise for hair regrowth in mice with a hair loss condition.

Ruxolitinib may help treat hair loss by reducing inflammation, promoting hair growth signals, and protecting hair follicle immunity.

Mesenchymal stem cell therapy may help treat alopecia areata by promoting hair growth and reducing inflammation.

Carboxytherapy may help increase hair growth in alopecia patients but requires ongoing treatment.

Laser and light therapies, especially the 308 nm excimer laser, are effective and safe for treating alopecia areata, but more research is needed.

Superficial cryotherapy is effective and safe for treating alopecia areata, with better results when used early and frequently.

Alopecia Areata is an autoimmune hair loss condition that needs more research for better treatments.

Alopecia Areata is an autoimmune disease causing hair loss in patches, often starting before age 20, and while some cases recover on their own, treatments include topical corticosteroids, minoxidil, and promising new methods like IL-31 antibodies and 308-nm Excimer laser therapy.

Blocking interferon-gamma helps prevent and treat hair loss in Alopecia Areata.

The multi-injection plate is a less painful and more efficient method for treating patchy hair loss.

Oxidative stress plays a significant role in alopecia areata, and new treatments may include JAK inhibitors and antioxidants.

Dupilumab treatment reduces Th2-related markers and helps hair growth in alopecia areata, showing Th2's role in the condition.

New targeted immunotherapies are improving treatment for inflammatory skin diseases.

Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.

The document concludes that understanding and treatments for alopecia areata have significantly advanced, now recognizing it as an autoimmune disorder.

Certain blood miRNAs are linked to severe alopecia areata and could lead to new treatments.

EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.

Alopecia areata patients have varied cancer risks, with some cancers being lower and others higher.

Wigs significantly improve the well-being of people with severe hair loss.

High-dose corticosteroids and methotrexate had a modest effect on severe childhood alopecia, but side effects and relapse were concerns.

ULBP3 could be a marker for diagnosing alopecia areata incognita and may be linked to its cause and development.

Multiple courses of pulse corticosteroid therapy improve hair growth in alopecia areata patients with minimal side effects.

The MTHFR C677T mutation may increase the risk of alopecia areata in the Turkish population.

Alopecia areata causes hair loss due to an immune attack on hair follicles, influenced by genetics and environment.

Alopecia areata patients, especially women with nail issues or atopic diseases, are at higher risk for other autoimmune diseases.

Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.

Mesenchymal stem cells may help treat hair loss by improving hair cell growth and reducing inflammation.